Characteristics and Outcomes of Second Malignant Neoplasms after Childhood Cancer Treatment: Multi-Center Retrospective Survey by �쑀泥좎＜ & �븳�젙�슦
© 2016 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Characteristics and Outcomes of Second Malignant Neoplasms 
after Childhood Cancer Treatment: Multi-Center Retrospective 
Survey
This retrospective study investigated the clinical characteristics and outcomes of second 
malignant neoplasms (SMNs) in survivors of childhood cancer from multiple institutions in 
Korea. A total of 102 patients from 11 institutions who developed SMN after childhood 
cancer treatment between 1998 and 2011 were retrospectively enrolled. The most common 
primary malignant neoplasms (PMNs) were central nervous system (CNS) tumors (n = 17), 
followed by acute lymphoblastic leukemia (n = 16), non-Hodgkin lymphoma (n = 13), and 
osteosarcoma (n = 12). The most common SMNs were therapy-related myeloid neoplasms 
(t-MNs; acute myeloid leukemia [AML], 29 cases; myelodysplastic syndrome [MDS], 12 
cases), followed by thyroid carcinomas (n = 15) and CNS tumors (n = 10). The median 
latency period was 4.9 years (range, 0.5-18.5 years). Among 45 patients with solid tumors 
defined as an SMN, 15 (33%) developed the lesion in a field previously subjected to 
radiation. The 5-year overall survival (OS) rate of patients with an SMN was 45% with a 
median follow-up time of 8.6 years. Patients with AML, MDS, and CNS tumors exhibited 
the poorest outcomes with 5-year OS rates of 18%, 33%, and 32%, respectively, whereas 
those with second osteosarcoma showed comparable outcomes (64%) to patients with 
primary counterpart and those with second thyroid carcinoma had a 100% OS rate. 
Further therapeutic efforts are recommended to improve the survival outcomes in patients 
with SMNs, especially in cases with t-MNs and CNS tumors.
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INTRODUCTION
The outcomes of childhood cancer have improved in recent decades, and the number 
of long-term survivors of childhood cancer is expected to increase significantly in the 
future. Survivors of childhood cancer are at increased risk for the development of vari-
ous late events, among which second malignant neoplasms (SMNs) are among the 
most serious. SMNs are the second most common cause of mortality among 5-year 
survivors of childhood cancer, behind only recurrence of the primary malignant neo-
plasm (PMN) (1).
 Several large cohort studies have shown that the risk of developing an SMN increas-
es 3- to 10-fold among childhood cancer survivors compared with the general popula-
tion (2-5). The Childhood Cancer Survivor Study (CCSS), the largest cohort study of 
childhood cancer survivors to date, reported a cumulative risk of developing SMN of 
3.2% at 20 years and 9.3% at 30 years of follow-up (6). Racial and ethnic differences can 
affect the epidemiology and outcomes of both SMN and PMN. Indeed, large study 
groups, such as the CCSS, British Childhood Cancer Survivor Study Group (BCCSS), 
and Nordic cohort, have reported outcomes of childhood cancer survivors with SMNs 
from western countries (4-6). However, no well-organized, comprehensive cohort of 
childhood cancer survivors has been reported for populations in Asia. Additionally, 
data about SMNs in childhood cancer survivors are scarce in Korea. Although a previ-
ous retrospective study reported the outcomes of patients with SMNs from 6 institu-
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tions in Korea between 1981 and 1997, only a small number of 
patients with a limited spectrum of disease were enrolled for 
that analysis (7). 
 Our present study aimed to further extend that previous study 
by investigating the clinical characteristics and outcomes of 
SMNs in survivors of childhood cancer who were retrospective-
ly surveyed from multiple institutions in Korea. Our findings 
are expected to provide baseline data for future cohort studies.
 
MATERIALS AND METHODS
Design and patients
A multicenter, retrospective questionnaire survey on SMNs was 
conducted after the treatment of childhood cancers. Question-
naires were sent to 26 member hospitals of the Korean Society 
of Pediatric Hematology-Oncology and responses were receiv-
ed from 14 hospitals (54%). Patients were registered if the PMN 
was diagnosed prior to the age of 21 years and if they had re-
ceived chemotherapy with or without radiotherapy. SMN was 
defined as a new neoplasm that developed after the primary 
cancer, not including the recurrence of the PMN. A total of 102 
patients from 11 hospitals who were diagnosed with a PMN be-
tween 1998 and 2011 were eligible for our present analyses.
 The case report form recorded demographic characteristics 
(sex, age, and cancer predisposition syndrome), and data about 
the PMN (histological diagnosis and sites of primary and meta-
static disease), treatments (chemotherapy, radiotherapy, surgi-
cal procedures, and hematopoietic stem cell transplantation 
[HSCT]), and about the SMN (date of diagnosis, histological 
type, site, extent of disease, therapy, and outcome). 
Statistical analysis
The Student t-test was used to compare differences between 
parametric variables. The Mann-Whitney U test was used to 
compare non-parametric data. The Kaplan-Meier method was 
used to estimate survival probabilities. A threshold of P < 0.05 
was set for statistical significance. All statistical analyses were 
performed using SPSS version 21.0 (Statistical Package for the 
Social Sciences; Chicago, IL, USA). 
Ethics statement
This study was approved by the institutional review board of 
Asan Medical Center, Seoul, Korea (IRB No. 2015-0941). Inform-
ed consent was waived by the board. 
RESULTS
Demographic data
The median patient age at the diagnosis of SMN was 12.7 years 
(range, 2.5-29.4 years) and at the diagnosis of PMN was 6.6 years 
(range, 0-19.7 years). Fourteen patients (13.7%) were older than 
20 years at the diagnosis of SMNs. The overall male-to-female 
ratio was 1.22:1. The median follow-up period was 8.6 years 
(range, 1.2-27.5 years). The study cohort included 6 patients 
(6%) with cancer predisposition syndrome, 4 patients with bi-
lateral retinoblastoma (including those who subsequently de-
veloped osteosarcoma [2 cases], juvenile myelomonocytic leu-
kemia [1 case], and mesenchymal sarcoma [1 case]), 1 patient 
with neurofibromatosis type 1 (who had a malignant peripheral 
nerve sheath tumor as the PMN and subsequently developed 
therapy-related acute myeloid leukemia [AML]), and 1 patient 
with Li-Fraumeni syndrome (who had rhabdomyosarcoma as 
the PMN and subsequently developed anaplastic astrocytoma).
Characteristics of the PMNs and SMNs
Table 1 presents the distribution of PMNs and SMNs. The most 
common PMNs were central nervous system (CNS) tumors 
(n = 17; 9 with medulloblastoma, 3 with germ cell tumors, 5 
with others), followed by acute lymphoblastic leukemia (ALL; 
n = 16), non-Hodgkin lymphoma (NHL; n = 13), and osteosar-
coma (n = 12). The most common SMNs were therapy-related 
myeloid neoplasms (t-MNs) (29 cases of AML and 12 cases of 
myelodysplastic syndrome [MDS]; 40.2%), followed by thyroid 
carcinoma (n = 15; 14.7%), CNS tumors (n = 10; 9.8%), and os-
teosarcoma (n = 8; 7.8%). 
 For the common types of SMN, the most frequent type of 
PMNs in patients with t-MNs (n = 41) were osteosarcoma (n = 10) 
and CNS tumors (n = 9). For patients with second thyroid car-
cinoma (n = 15), there was no preference for the preceding type 
of PMN. For patients with second CNS tumors (n = 10), the 
most common PMNs were ALL (n = 4) and other CNS tumors 
(n = 3). The most common combination was t-MNs after either 
osteosarcoma (n = 9) or CNS tumors (n = 9).
 The median interval between diagnosis of the PMN and SMN 
was 4.9 years (range, 0.5-18.5 years). The interval was shortest 
for AML (median, 2.8 years; range, 0.5-13.4 years) and MDS 
(median, 2.7 years; range, 1.7-8.4 years) as the SMN, and was 
longer for solid tumors, such as osteosarcoma (median, 6.3 years; 
range, 3.6-14.8 years), thyroid cancer (median, 6.8 years; range, 
4.1-18.5 years), and CNS tumors (median, 9.3 years; range, 1.9-
12.6 years; Fig. 1). The mean interval was shorter for second he-
matologic malignancies (3.9 years) compared with second solid 
tumors (8.7 years; P = 0.020).
 Among 41 patients with t-MNs, 23 patients had received a 
median cumulative etoposide dose of 2,377 mg/m2 (range, 334-
4,837 mg/m2) for their PMNs, 21 patients a median doxorubi-
cin-equivalent cumulative dose of 291 mg/m2 (range, 35-451 
mg/m2), 16 patients a median cumulative cyclophosphamide 
dose of 9,040 mg/m2 (range, 689-26,727 mg/m2), 18 patients a 
median cumulative ifosfamide dose of 52,593 mg/m2 (range, 
2,320-147,170), 17 patients a median cumulative cisplatin dose 
of 293 mg/m2 (range, 85-835 mg/m2), and 13 patients a median 
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cumulative carboplatin dose of 4,125 mg/m2 (range, 1,252-10,411 
mg/m2). In addition to chemotherapy, sixteen patients had re-
ceived craniospinal (n = 7) or focal (n = 9) irradiation for their 
PMNs. 
 Cytogenetic abnormalities in t-MDS included combined 
chromosome 7 and 5 abnormalities (n = 3), chromosome 7 ab-
normalities (n = 3), complex karyotypes (n = 2), and other ab-
normalities (n = 4). For therapy-related AML (t-AML; n = 29), 
cytogenetic abnormalities included 11q23 translocations (n = 13), 
a normal karyotype (n = 5), complex karyotypes (n = 4), t(8;21) 
(n = 1), and t(15;17) (n = 1).
 The most common histological subtypes of second thyroid 
carcinoma (n = 15) were papillary carcinoma (n = 9), followed 
by follicular (n = 4), poorly differentiated (n = 1), and undiffer-
entiated (n = 1) carcinoma. The histological subtypes of second 
CNS tumors (n = 10) were as follows: 2 embryonal tumors (1 
medulloblastoma and 1 supratentorial primitive neuroectoder-
mal tumor [PNET]), 2 low-grade gliomas (1 oligodendroglioma 
and 1 pilocytic astrocytoma of the optic pathways), and 5 high-
grade gliomas (3 glioblastoma, 1 anaplastic astrocytoma, and 1 
anaplastic oligodendroglioma), and 1 brainstem glioma.
SMNs after radiation therapy
Among 45 patients with a second solid tumor, 15 (33%) were 
reported to have developed this SMN in a previous radiation 
field (Table 2). The most frequent SMNs after radiation therapy 
were CNS tumors (n = 5) and thyroid carcinoma (n = 5), fol-
lowed by osteosarcoma (n = 2), and others (n = 3). Indications 
of radiation treatment for PMN in second CNS tumors included 
prophylactic cranial radiation in 3 patients (1 case with NHL 
and 2 cases with ALL) and therapeutic craniospinal radiation in 
2 cases with primary CNS tumors. For patients with second thy-
roid carcinoma, PMN was Hodgkin lymphoma in 2, ALL in 1, 
neuroblastoma in 1, and rhabdomyosarcoma in 1. Five of 10 
subsequent CNS tumors (50%) developed after prior radiation 
therapy, 5 of 15 subsequent thyroid carcinomas (33%) and 2 of 
8 subsequent osteosarcomas (25%). The median latency period 
of solid tumors after radiation therapy was 9.5 years (range, 5.3-
Table 1. Second malignant neoplasms in the study patients with the indicated primary malignant neoplasm
P rimary malignant 
neoplasms
Second malignant neoplasms
ALL AML MDS BAL CML JMML NHL HL CNS OSA RMS STS Thyroid
Carcino-
ma
LCH Total
ALL -   4 - 2 - - 1 -   4 1 1 -   2 - 1   16
AML - -   1 - - - - - - - - - - - -     1
BAL - - - - - - - - - - - - - 1 -     1
NHL 4   4 - - - - - 1   1 1 - -   1 1 -   13
HL - - - - - - - - - - - -   2 - -     2
CNS -   4   5 1 - - 1 -   3 1 1 - - 1 -   17
NBL -   2 - - - - 1 - - 1 - -   3 1 -     8
RBL - - - - - 1 - - - 2 - 1 - - -     4
HBL - -   1 - - - - - - - - - - 1 -     2
PPB - - - - - - - - - - - -   1 - -     1
Wilms - - - - - - - - - - - 1   1 - -     2
CCSK - - - - - - - -   1 - - - - - -     1
ACC - - - - - - - - - - - -   2 - -     2
OSA 1   8   2 - 1 - - - - - - - - - -   12
EFT -   2   1 - - - - - - - - -   1 - -     4
RMS -   1   1 - - 1 - -   1 - - -   1 1 -     6
STS -   1   1 - - - - - - 1 - 1 - - -     4
GCT -   3 - - - - - - - 1 - -   1 - -     5
LCH - - - - - - 1 - - - - - - - -     1
Total 5 29 12 3 1 2 4 1 10 8 2 3 15 6 1 102
ACC, adrenocortical carcinoma; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BAL, biphenotypic acute leukemia; CCSK, clear cell sarcoma of kidney; CNS, 
central nervous system; EFT, Ewing family tumors; GCT, germ cell tumors; HBL, hepatoblastoma; HL, Hodgkin lymphoma; LCH, Langerhans cell histiocytosis; NBL, neuroblasto-
ma; NHL, Non-Hodgkin lymphoma; OSA, osteosarcoma; PPB, pleuropulmonary blastoma; RBL; retinoblastoma; RMS, rhabdomyosarcoma; STS, soft tissue sarcoma.
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Fig. 1. The latency period between the diagnosis of primary and second malignant 
neoplasms.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CNS, central ner-
vous system; MDS, myelodysplastic syndrome.
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14.0 years), while that of solid tumors not associated with radia-
tion was 8.0 years (range, 1.1-18.5 years; P = 0.134). The median 
latency periods for CNS tumors and thyroid carcinoma after ra-
diation therapy were 10.3 years (range, 8.6-12.6 years) and 9.5 
years (range, 5.7-13.3 years), respectively, whereas those of CNS 
tumors and thyroid carcinoma that were not associated with 
radiation were 8.8 years (range, 1.9-9.6 years) and 6.5 years (range, 
4.1-18.5 years), respectively (P = 0.095 and 0.371).
SMNs after HSCT
A total of 20 patients among the patients with SMNs had been 
received HSCT before, including 17 patients after high-dose 
chemotherapy with autologous stem cell transplantation (HDCT/ 
ASCT) and 3 patients after allogeneic HSCT. The most frequent 
SMN following HDCT/ASCT was AML (n = 7), followed by thy-
roid carcinoma (n = 4), non-thyroid carcinoma (n = 2), osteo-
sarcoma (n = 1), rhabdomyosarcoma (n = 1), and other soft tis-
sue sarcomas (n = 2). Among 4 patients with thyroid carcino-
ma, 1 patient had received total body irradiation as a compo-
nent of preparative regimen for HDCT/ASCT. The SMNs fol-
lowing allogeneic HSCT included AML (n = 1), MDS (n = 1), 
and squamous cell carcinoma (n = 1).
Outcomes of SMNs
The 5-year overall survival (OS) rate of patients with an SMN 
was 45% (Fig. 2A) with a median follow-up time of 8.6 years. 
Table 2. Characteristics of radiation-associated second malignant neoplasms
Case Second malignant neoplasm Primary malignant neoplasm Site Dose, cGy Latency period, yr
  1 Anaplastic oligodendroglioma ALL Cerebral hemisphere 1,800 8.6
  2 Oligodendroglioma ALL Cerebral hemisphere 1,800 12.6
  3 Glioblastoma Medulloblastoma Cerebellum 5,580 10.3
  4 Glioblastoma Medulloblastoma Cerebellum 5,580 9.5
  5 sPNET Lymphoblastic lymphoma Cerebral hemisphere 1,800 11.4
  6 Osteosarcoma Medulloblastoma Skull 5,500 5.3
  7 Osteosarcoma Lymphoblastic lymphoma Iliac bone 3,800 6.8
  8 Thyroid carcinoma (papillary) ALL Craniospinal 2,400 9.1
  9 Thyroid carcinoma (papillary) Hodgkin Thyroid 2,340 8.4
10 Thyroid carcinoma (undifferentiated) Hodgkin Thyroid 1,950 13.4
11 Thyroid carcinoma (follicular) Rhabdomyosarcoma Neck 4,430 10.9
12 Thyroid carcinoma (follicular) Neuroblastoma Total body irradiation 999 5.7
13 Renal cell carcinoma Neuroblastoma Kidney 1,500 7.5
14 Signet ring cell carcinoma Rhabdomyosarcoma Rectum 4,140 10.3
15 MPNST Malignant rhabdoid tumor Neck 6,500 14.0
ALL, acute lymphoblastic leukemia; MPNST, malignant peripheral nerve sheath tumor; sPNET, supratentorial primitive neuroectodermal tumor.
Fig. 2. Survival outcomes of the patients with second malignant neoplasm. (A) The 5-year overall survival rates of patients with second malignant neoplasms. (B) The 5-year 
overall survival rates of patients with AML, MDS, CNS tumors, osteosarcoma, and thyroid carcinoma.
AML, acute myeloid leukemia; CNS, central nervous system; MDS, myelodysplastic syndrome.
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The 5-year OS rates of patients with common types of SMN, in-
cluding AML, MDS, CNS tumors, osteosarcoma, and thyroid 
carcinoma, were 18%, 33%, 32%, 64%, and 100%, respectively 
(Fig. 2B). 
 For therapy-related MDS (t-MDS; n = 12), 5 patients had ear-
ly MDS (refractory anemia in 2 cases, MDS associated with iso-
lated del(5q) in 1 case, and unclassifiable in 2 cases) and 7 pa-
tients had advanced MDS (refractory anemia with excess blasts 
[RAEB]-1 in 1 case, RAEB-2 in 4 cases, and RAEB in transforma-
tion in 1 case). The 5-year OS rates of patients with early and 
advanced MDS were 50% and 20%, respectively. The 5-year OS 
rates for the patients who received allogeneic HSCT for t-AML 
(n = 14) and t-MDS (n = 6) were 35% and 40%, respectively, 
while those for the patients with t-AML (n = 15) and t-MDS 
(n = 6) who did not were 0% and 25%.
 For second thyroid carcinomas (n = 15), all of the patients for 
whom treatment data was available (n = 13) were reported to 
have undergone thyroidectomy. No patient died of a second 
thyroid carcinoma.
 For second CNS tumors (n = 10), 2 patients with embryonal 
tumors received surgery, radiotherapy and chemotherapy, and 
a patient with medulloblastoma survived, whereas a patient 
with PNET died of refractory disease. For high-grade gliomas, 2 
patients (1 with glioblastoma and 1 with anaplastic oligoden-
droglioma) underwent surgery and then received chemothera-
py, and other 3 patients received chemotherapy alone. Among 
them, only 1 patient with anaplastic oligodendroglioma sur-
vived, whereas other 4 patients died of refractory disease. A pa-
tient with brainstem glioma received radiotherapy and chemo-
therapy, but died of refractory disease. Two patients with low-
grade glioma received radiotherapy and chemotherapy, and 
survived. The 5-year OS rate of all second CNS tumors was 35%. 
Notably, the outcome of patients with high-grade or brainstem 
glioma was very poor with a 5-year OS of just 17%.
 
DISCUSSION
Our current report presents the findings of a second retrospec-
tive survey of SMNs in childhood cancer survivors from multi-
center in Korea. In the first survey, 24 patients with SMN treated 
from 1981-1997 had been enrolled from 6 institutions, includ-
ing 7 cases of AML, 5 cases of osteosarcoma, and 5 cases of ALL 
(7). Our present study included a broader spectrum of SMN 
cases in which t-MNs were the most common SMN to be re-
corded during a median 8.6 years follow-up period, similar to 
the first report. Notably, t-MNs after CNS tumors or osteosarco-
ma were the most common combination of malignancies ob-
served. However, in contrast to the first report, our present anal-
yses indicated that thyroid carcinoma and CNS tumors repre-
sented other prevalent SMNs. The outcomes of patients with 
second t-MNs were poorer than those with de novo AML or 
MDS, whereas a second osteosarcoma showed a comparable 
outcome to a primary osteosarcoma, and patients with second 
thyroid carcinoma exhibited a 100% survival rate.
 Previous studies have each reported a diverse spectrum of 
SMNs. The study of the CCSS cohort (median age, 34 years) re-
ported non-melanoma skin cancer, breast cancer, thyroid can-
cer, and CNS tumors as the most common SMNs (6). A long-
term follow-up study of the BCCSS cohort, with a median fol-
low-up time of 24.3 years, reported the most frequently observ-
ed SMNs as CNS tumors and non-melanoma skin cancer, fol-
lowed by digestive, genitourinary, and breast cancers (6). A pop-
ulation-based case-control study conducted in 5 Nordic coun-
tries with an average follow-up period of 7.5 years reported that 
CNS tumors, bone and soft tissue tumors, breast cancer, diges-
tive tract cancer, and leukemia were the most common SMNs 
(8). A regional cohort study conducted in France reported over 
a median follow-up of 9.8 years that the most common SMNs 
were thyroid carcinomas, followed by bone tumors, leukemia, 
post-transplant lymphoproliferative disease, and CNS tumors 
(9). A single-center study from Hong Kong reported t-MNs and 
CNS tumors as the most frequent SMNs over a median follow-
up of 5.3 years (10). 
 These significant discrepancies among studies on the inci-
dence of different SMNs are a consequence of differences in 
the distribution of PMNs, the follow-up duration, and ethnicity 
of the patients analyzed. Long-term follow-up studies are more 
likely to include solid tumors because the latency period of a 
solid tumor is greater than that of a hematologic malignancy. In 
the present study, the latency period of t-AML and t-MDS was 
2.8 and 2.7 years, respectively, which were comparable to previ-
ous studies (11-13). Additionally, the rarity of Hodgkin lympho-
ma in Korea explains the low incidence of breast cancer, which 
has been associated with the radiation fields that are used to 
treat Hodgkin lymphoma. Because the median follow-up peri-
od of the BCCSS study was greater than 20 years and the medi-
an age of the CCSS cohort was 34 years, their reports included 
many adult-type cancers, such as digestive, genitourinary, and 
breast cancers. However, because our present questionnaire 
survey was limited to pediatricians and the median age of our 
study cohort was 12.7 years with a relatively short follow-up 
time, our cohort was less likely to include adult-type solid can-
cers and more likely to include t-MNs. Thus, longer follow-up 
would change the distribution of SMNs, resulting in the increase 
of solid tumors as SMNs. Therefore, our findings should be in-
terpreted with caution, as the data were limited to childhood 
cancer survivors during adolescence and early adulthood. To 
overcome this limitation and obtain a more accurate estimate 
of SMNs in childhood cancer survivors in Korea, a comprehen-
sive cohort follow-up study will be required. 
 In our present analyses, t-MNs were the most common SMN, 
perhaps because of the short latency periods of t-MNs, the short 
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follow-up time of the study, and the limitation of our question-
naire survey to pediatric hemato-oncologists. It was difficult to 
definitely distinguish t-MNs as SMNs from relapse of PMNs 
with immunophenotypic changes, especially when latency pe-
riods between primary and second leukemia was short. To re-
duce the possibility of relapse of PMNs, we only included the 
patients who developed typical cytogenetic aberrations of t-
MNs such as 11q23 translocations or chromosome 7 and 5 ab-
normalities, or distinguished cytogenetic aberrations from pri-
mary leukemia. The most common cytogenetic abnormalities 
were 11q23 translocations in t-AML and chromosome 7 and 5 
abnormalities in t-MDS, a finding that is consistent with previ-
ous reports (14,15). Previously, outcomes of t-MNs have been 
reported to be dismal (11,12,14,16). In our current study cohort, 
the outcomes for patients with t-MNs also appeared to be poor-
er than patients with de novo AML or MDS. Although the sur-
vival rate of the patients with t-MN who received allogeneic 
HSCT was better that of those patients who did not, our data do 
not suggest that allogeneic HSCT is beneficial in these patients, 
because those patients who did not achieve complete remis-
sion or died due to treatment toxicity could not proceed to HSCT. 
Thus, future studies of the role of allogeneic HSCT for t-MNs are 
needed.
 Primary thyroid carcinoma during childhood is uncommon. 
A single-center study has reported that 17 of 25 patients with 
thyroid carcinoma presented with an SMN, and that 12 of these 
cases (71%) with second thyroid carcinoma had received radia-
tion to the thyroid gland during therapy for their primary can-
cer; most of those primary cases were Hodgkin lymphoma (17). 
Another study showed that 68% of the second thyroid cancers 
developed within the field of radiation (18). In our present co-
hort, only 5 of 15 patients (33%) developed with previous radia-
tion field. Relatively low incidence of radiation-associated thy-
roid cancers can be attributed to low incidence of Hodgkin lym-
phoma in Korea. Treatments for patients with second thyroid 
carcinomas have yielded excellent outcomes and therapeutic 
approaches for such lesions can therefore be similar to those 
used for primary thyroid carcinoma.
 The most important risk factor for the development of sec-
ond CNS tumors is cranial radiation, and meningioma and gli-
oma have been reported to be common therapy-related brain 
tumors (19,20). In our present cohort, only 5 of 10 (50%) second 
CNS tumor cases were associated with radiation, and most of 
these patients had glioma and seemed to require a longer la-
tency period than patients who did not receive cranial radia-
tion. Typically, meningioma associated with radiation requires 
a long latency period (>10 years) (19-21), so it was not included 
in our present study series. In addition, our present study sur-
veyed the patients who received chemotherapy and did not in-
clude those who received radiotherapy alone for primary CNS 
tumors. The outcomes for patients with second CNS tumors 
were very poor in our present study, especially for high-grade 
glioma cases. However, this finding is consistent with the sur-
vival rates of de novo high-grade glioma, so the outcomes of 
subsequent CNS tumors remain to be investigated.
 Thyroid cancers, brain tumors, and breast cancers has been 
well known to be associated with previous therapeutic radia-
tion. Besides, bone and soft tissue sarcomas, genitourinary, or 
gastrointestinal cancers have been reported to develop in previ-
ous radiation filed (22). Previous epidemiologic studies have 
reported the dose-response relationship for SMNs after thera-
peutic radiation, with the exception of thyroid cancers, for which 
there was a linearly increased risk up to 20 Gy, and then a de-
crease in risk for doses > 20 Gy (23). 
 In the present study, the latency periods for SMNs after radi-
ation therapy seemed slightly longer than those not associated 
with previous radiation, but without statistical significance. One 
explanation for this tendency is that SMNs after radiation ther-
apy require more than 5 years of latency period, because at least 
a 5-year lag has been shown between radiation exposure and 
second cancer development (22). 
 Our present study had several limitations of note. First, we 
could not collect epidemiological data because our analyses 
were based on a retrospective medical review rather than on 
information from a registry. Our data could not show a cumula-
tive risk of SMNs among childhood cancer survivors or the inci-
dence of SMNs in the selected patients who had risk factors such 
as cranial radiation or cancer predisposition syndromes. Also, 
the estimation of frequencies of SMN was likely to be hampered 
by a selection bias. Thus, our study does not represent the epi-
demiological aspects of SMNs after childhood cancer in Korea, 
but provides the clinical features and outcomes of a retrospec-
tive, selected case series. Second, our present questionnaire 
survey was limited to pediatric hemato-oncologists. For this 
reason, we could not collect data on adult-type, very late can-
cers because of our short follow-up period and difficulties in 
monitoring childhood cancer survivors into adulthood. Thus, 
our results should be interpreted cautiously, limiting to an early 
follow-up period in a pediatric hemato-oncology clinic. 
 In conclusion, the most common types of SMNs in childhood 
cancer survivors, which were encountered in a pediatric hema-
to-oncology clinic during the early follow-up period, were t-
MNs, thyroid carcinoma, CNS tumors, and osteosarcoma. The 
outcomes of patients with second t-MNs and CNS tumors were 
especially poor, whereas patients with second osteosarcomas 
showed comparable outcomes to cases with its primary coun-
terpart. Additionally, second thyroid carcinomas had no signifi-
cant impact on long-term survival. Our current study did not 
evaluate the relative risks of SMNs based on epidemiological 
data and a nationwide childhood cancer survivor registry should 
therefore be established in Korea to evaluate the incidence and 
outcomes of SMNs. The findings in our current study can pro-
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vide baseline data for future multi-center trials of childhood 
SMNs. Further therapeutic efforts will be required to improve 
the survival outcomes in patients with SMNs, especially in cas-
es with t-MNs and CNS tumors.
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